Skip to main content

Clinical and Translational Oncology

Ausgabe 6/2023

Inhalt (30 Artikel)

REVIEW ARTICLE

Non-coding RNAs as potential biomarkers of gallbladder cancer

Yan Lv, Wanyue Yin, Zhikai Zhang

REVIEW ARTICLE

A novel regulator in cancer initiation and progression: long noncoding RNA SHNG9

Mingxing Zhao, Yang Zhang, Shen Shen

REVIEW ARTICLE

Lactobacillus for ribosome peptide editing cancer

Shousong Yue, Qiuxia He, Jean-François Picimbon

Open Access REVIEW ARTICLE

Bcl-2 pathway inhibition in solid tumors: a review of clinical trials

Ioanna Ploumaki, Efthymios Triantafyllou, Ioannis-Alexios Koumprentziotis, Konstantinos Karampinos, Konstantinos Drougkas, Ioannis Karavolias, Ioannis Trontzas, Elias A. Kotteas

Open Access REVIEW ARTICLE

Histone methylation in pre-cancerous liver diseases and hepatocellular carcinoma: recent overview

Evelina Charidemou, Costas Koufaris, Maria Louca, Antonis Kirmizis, Teresa Rubio-Tomás

RESEARCH ARTICLE

Cancer-associated fibroblasts contribute to cancer metastasis and apoptosis resistance in human ovarian cancer via paracrine SDF-1α

Jie-min Dai, Ke Sun, Chang Li, Min Cheng, Jun-hua Guan, Li-na Yang, Li-wen Zhang

RESEARCH ARTICLE

Identification of a cuproptosis-related lncRNA prognostic signature in lung adenocarcinoma

Ran Chen, Haichao Luo, Qitian Chen, Changying Wang

RESEARCH ARTICLE

Role of synaptotagmin 13 (SYT13) in promoting breast cancer and signaling pathways

Yi-Dan Zhang, Rui Zhong, Jin-Quan Liu, Zhen-Xuan Sun, Teng Wang, Jin-Tao Liu

RESEARCH ARTICLE

LncRNA HOTAIR enhances RCC2 to accelerate cervical cancer progression by sponging miR-331-3p

Gulimire Buranjiang, Ailikemu Abuduwanke, Xiaowen Li, Guzalinuer Abulizi

RESEARCH ARTICLE

Prediction model of colorectal cancer (CRC) lymph node metastasis based on intestinal bacteria

Wu Yinhang, Zhuang Jing, Zhou Jie, Jin Yin, Wu Xinyue, Song Yifei, Fan Zhiqing, Wu Wei, Han Shuwen

Open Access RESEARCH ARTICLE

The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer

Wei Wang, Tingting Zhu, Hao Chen, Yongzhong Yao

Open Access RESEARCH ARTICLE

A novel prognostic model of methylation-associated genes in acute myeloid leukemia

Meiyu Chen, Zhao Zeng, Wei Qin, Xiaohui Cai, Xuzhang Lu, Suning Chen

RESEARCH ARTICLE

Genetic architecture of mammographic density as a risk factor for breast cancer: a systematic review

Asma Khorshid Shamshiri, Maryam Alidoust, Mahboubeh Hemmati Nokandei, Alireza Pasdar, Fahimeh Afzaljavan

Open Access Research Article

Vaginal dilator use more than 9 months is a main prognostic factor for reducing G2‑late vaginal complications in 3D‑vaginal‑cuff brachytherapy (interventional radiotherapy)?

Yaowen Zhang, Faegheh Noorian, Rosa Abellana, José Rochera, Antonio Herreros, Gabriela Antelo, Valentina Lancellotta, Luca Tagliaferri, Qian Han, Aureli Torne, Angeles Rovirosa

RESEARCH ARTICLE

Ten-year experience of bone SBRT in breast cancer: analysis of predictive factors of effectiveness

Héctor Pérez-Montero, Alicia Lozano, Rodolfo de Blas, Juan José Sánchez, Evelyn Martínez, María Laplana, Miguel Gil-Gil, Amparo Garcia-Tejedor, Sonia Pernas, Catalina Falo, Óscar Godino, Maria J. Pla, Ferrán Guedea, Arturo Navarro-Martin

RESEARCH ARTICLE

Frequently mutated genes in predicting the relapse of stage I lung adenocarcinoma

Wen Rao, Lujie Yang, Nan Dai, Liang Zhang, Jie Liu, Bo Yang, Mengxia Li, Jinlu Shan, Qiushi Wang, Dong Wang

RESEARCH ARTICLE

Non-inferior efficacy of non-surgical treatment to surgical treatment in patients with nonmetastatic head and neck rhabdomyosarcoma: a SEER-based study

Wenjing Liang, Langman Li, Miao Wang, Yixin Liu, Ye Qiu, Boyu Zhang, Qiuji Wu, Yongchang Wei

RESEARCH ARTICLE

Disruption of mitochondrial oxidative phosphorylation by chidamide eradicates leukemic cells in AML

Jun-Dan Wang, Jue-Qiong Xu, Zi-Jie Long, Jian-Yu Weng

RESEARCH ARTICLE

Clinical characteristics and outcomes of follicular lymphoma patients with extranodal involvement: analysis of a series of 1090 cases in China

Zhijuan Lin, Jie Zha, Shuhua Yi, Zhifeng Li, Lingyan Ping, Xiaohua He, Liyuan Fan, Haifeng Yu, Zhong Zheng, Wei Xu, Feili Chen, Ying Xie, Biyun Chen, Huilai Zhang, Li Wang, Kaiyang Ding, Wenyu Li, Haiyan Yang, Weili Zhao, Lugui Qiu, Zhiming Li, Yuqin Song, Bing Xu

Research Article

The prognostic values of FOXP3+ tumor-infiltrating T cells in breast cancer: a systematic review and meta-analysis

Yalan Sun, Ying Wang, Fang Lu, Xianghong Zhao, Zhenlin Nie, Bangshun He

RESEARCH ARTICLE

Metabolic heterogeneity in early-stage lung adenocarcinoma revealed by RNA-seq and scRNA-seq

Yang Zhang, Jiang Shi, Junfang Luo, Cong Liu, Lixu Zhu

RESEARCH ARTICLE

Bioinformatic analysis of single-cell RNA sequencing dataset dissects cellular heterogeneity of triple-negative breast cancer in transcriptional profile, splicing event and crosstalk network

Jin Qiu, Lu Ma, Tingting Wang, Juntong Chen, Dongmei Wang, Yuhan Guo, Yin Li, Xinran Ma, Geng Chen, Ying Luo, Xinghua Cheng, Lingyan Xu

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.